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Thin ﬁlament
γ-tropomyosinMissense mutations in human TPM3 gene encoding γ-tropomyosin expressed in slow muscle type 1 ﬁbers,
were associated with three types of congenital myopathies—nemaline myopathy, cap disease and congenital
ﬁber type disproportion. Functional effects of the following substitutions: Leu100Met, Ala156Thr, Arg168His,
Arg168Cys, Arg168Gly, Lys169Glu, and Arg245Gly, were examined in biochemical assays using recombinant
tropomyosinmutants and native proteins isolated from skeletalmuscle.Most, but not all, mutations decreased the
afﬁnity of tropomyosin for actin alone and in complex with troponin (±Ca2+). All studied tropomyosin mutants
reduced Ca-induced activation but had no effect on the inhibition of actomyosin cross-bridges. Ca2+-sensitivity of
the actomyosin interactions, aswell as cooperativity ofmyosin-induced activation of the thinﬁlamentwas affected
by individual tropomyosin mutants with various degrees. Decreased motility of the reconstructed thin ﬁlaments
was a result of combined functional defects caused by myopathy-related tropomyosin mutants. We conclude
that muscle weakness and structural abnormalities observed in TPM3-related congenital myopathies result from
reduced capability of the thin ﬁlament to fully activate actin–myosin cross-bridges.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Congenital myopathies are non-dystrophic muscle diseases char-
acterized by weakness and deformations of different muscle parts,
which impair motor and respiratory functions. Patients exhibit a
broad spectrum of symptoms—from very severe, leading to death in
early childhood, to benign late onset cases. Because the dysfunction of
the thin ﬁlament proteins—actin, tropomyosin (TM), troponin (Tn)
and nebulin, are themost frequent causes of these diseases, myopathies
are sometimes called diseases of the thin ﬁlament [1,2].
Mutations in TPM3, a gene encoding the γ-tropomyosin isoform
(γ-TM) expressed in type 1 slow muscle ﬁbers, have been identiﬁed
in three types of congenital myopathies: nemaline myopathy (NM),
cap disease (CD) and congenital ﬁber type disproportion (CFTD)
[3–7]. Disproportion of ﬁber type is a histological abnormality observed
in all three myopathies. It is diagnosed when the diameter of type 1
ﬁbers is at least 12% smaller than the diameter of type 2 ﬁbers [8].
In CFTD disproportion of muscle ﬁbers is a central diagnostic featurew type 1 muscle ﬁbers; skTM,
opomyosin gene; Tn, troponin
D, congenital ﬁber type dispro-
yosin
tal Biology, Chodkiewicza 30,
x: +48 52 341 9184.
ska).
t of Biochemistry, Edmonton,
l rights reserved.[9]. However, the development of this change in patients suggests
that instead of being a disease entity in itself, ﬁber type dispropor-
tion stands at the crossroads of other types of myopathies [10]. The
major pathological feature of NM is the presence of nemaline bodies
(rod-like structures containing thin ﬁlament and Z-line proteins) in
muscle ﬁbers [11]. CD is characterized by the accumulation of cap-like
structures at the periphery of muscle cells, which are ﬁlled with dis-
organized actin ﬁlaments [12]. In both types of myopathy ﬁber type
disproportion is regarded as a secondary feature [10].
The ﬁrst known myopathy-causing mutation in TPM3 was the mis-
sense mutation Met9Arg [13]. Met9 is located in the N-terminal region
which is important for polymerization of TM along the actin ﬁlament,
binding of Tn complex and Ca-dependent regulation of actin–myosin
interactions [14]. Further studies revealed that myopathy-causing mu-
tations in TPM3 are not limited to the N-terminal region of γ-TM, but
are located throughout themolecule. To date 14myopathy relatedmuta-
tions in TPM3have been reported [3–7]. Althoughmost knownmutations
are responsible for one type of myopathy, the Arg168His, Arg168Cys and
Stop286Ser mutations have been linked to more than one myopathy
type.
The thinmuscle ﬁlament consists of ﬁlamentous actin and the regula-
tory proteins—tropomyosin and troponin. Tropomyosin is a two-chained
coiled coil protein extending along seven actin subunits. Due to
end-to-end interactions, TM can form long “cables” which bind on both
sides of actin stabilizing the ﬁlament. Together with the troponin
complex TM regulates muscle contraction by controlling actin–myosin
interactions in response to changes in Ca2+ concentrations [15]. The
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of periodicities. The ﬁrst type of periodicity is a heptapeptide repeat
(a–b–c–d–e–f–g) per two turns of theα helix with mostly hydrophobic
residues at positions a and d. The hydrophobic residues are located on
the same side of the TMchain and forma hydrophobic core of the coiled
coil (Fig. 1). The hydrophobic bondswithin the core and electrostatic in-
teractions between residues in positions e and g strongly stabilize the
coiled coil structure [16]. The second type of periodicity is formed by
homologous seven-fold repeats of charged and nonpolar amino acids,
which are located outside the coiled coil hydrophobic core (b, c and
f positions of the heptapeptide repeat) and are referred to as consensus
sites. Due to the twist of the coiled coil, the side-chains of the consensus
residues are similarly oriented relative to the coiled coil axis. This
arrangement can lead to the formation of periodic binding sites between
tropomyosin consensus sites and subunits of the actin ﬁlament [17].
The regulation of actin–myosin cross-bridge interactions is best
described by the steric blocking and cooperative/allosteric models
[18]. At low Ca2+ concentrations, binding of myosin heads to actin ﬁla-
ments is blocked by TM (blocked B-state). Ca2+ binding to TnC triggers
conformational changes in the TM-Tn regulatory complex, which shift
TM chains on the actin ﬁlament to allow myosin binding (closed
C-state). Full activation requires an isomerization of myosin heads to
the strongly bound “rigor” state (open M-state). It is a well known
phenomenon that in the presence of TM myosin cooperatively
switches the thin ﬁlament from the closed to open state. TM is therefore
a dual regulator, which inhibits the actin-activated myosin ATPase at
low myosin to actin ratios but activates it at high ratios. The presence
of Tn enhances the activatory and inhibitory effect of TM [18,19]. The
mechanisms of muscle thin ﬁlament regulation are complex, thus
even subtle changes in the regulatory proteins may lead to functional
defects of the whole muscle.
The prediction of functional changes associated with a speciﬁc
mutation in slow tropomyosin is necessary for precise diagnosis,
prognosis and application of the most efﬁcient therapy. To better under-
stand themolecular bases of TM-relatedmyopathies, in the presentwork
we compared the functional effects of seven missense mutations, which
were recently found in patients with CFTD, NM and CD [4,5,7]. Using
site-directed mutagenesis we introduced single mutations in rat striated
muscle αTM. This tropomyosin has been used previously in in vitro
studies [20]. The rat αTM isoform shares 92.6% amino acid identity
and 95.8% homology with human slow skeletal γTM (NCBI accession
numbers: P04692.3 for rat TM and NP_689476.2 for human isoform),
and is therefore regarded as a good model protein. The sites of all
myopathy-related mutations studied in the present work along with
the nearest amino acid residues are identical in human γTM and rat
αTM. The amino acid substitutions and their locations in the molecule
are shown in Table 1 and Fig. 1. Our goal was to ﬁnd relationships
between functional defects caused by the mutations and structural
features of TM, which owing to extensive studies are well understood.Fig. 1. Localization of myopathy-causing mutations in the coiled coil structure of
tropomyosin homodimer. The diagram shows two turns of α helical heptapeptides (a–g).
Residues a and d are usually hydrophobic and form core of the coiled coil.Themutationswere selected in order to address two speciﬁc questions:
(1) is there a correlation between the position of themutation in the TM
sequence and the functions of the thin ﬁlament; (2) is there a speciﬁc
pattern of functional defects, which can be associated with a particular
type of congenital myopathy. Functional analyses were done with the
use of biochemical methods and an in vitromotility assay.2. Materials and methods
2.1. Construction of TM myopathy-related mutants
Rat α-tropomyosin cDNA encoding fast skeletal muscle αTM
(skTM) was used as a template. cDNA cloned in pET11d was a gift
from Dr. Hitchcock-DeGregori. Mutants were made using PCR-based
oligonucleotide-directed mutagenesis (Stratagene). The primers were
synthesized and HPLC puriﬁed by the Laboratory of DNA Sequencing
and Oligonucleotide Synthesis, Institute of Biochemistry and Bio-
physics (Warsaw, Poland). skTM cDNA was modiﬁed by insertion
of theMet-Ala-Ser codons (shown in bold) at 5′-end using the following
oligonucleotide:
AS: 5′-GAAGGAGATCATATGGCTTCTATGGACGCCATCAAGAAGAAG‐3′
This modiﬁcation resulted in two amino acid N-terminal extension
(AlaSer), commonly used to compensate for the absence of acetylation
in bacterially expressed TM [21]. cDNA carrying 5′Met-Ala-Ser codons
was used as a template to generate myopathy mutants. The following
oligonucleotides were used as primers:
Leu100Met: 5′‐CAGCTGGTTGAGGAGGAGATGGATCGCGCTCAGGAG‐
3′
Ala156Tyr: 5′‐GAGGCCAAGCACATTACTGAAGATGCTGACCGAAAG‐3′
Arg168His: 5′‐CGAAAGTATGAAGAGGTGGCCCATAAGCTG GTCAT
CATC‐3′
Arg168Cys: 5′‐CGAAAGTATGAAGAGGTGGCCTGTAAGCTGGTCATC
ATC‐3′
Arg168Gly: 5′‐GAAGAGGTGGCCGGTGAGCTGGTCATCATC‐3′
Lys169Glu: 5′‐CGAAAGTATGAAGAGGTGGCCCGTGAGCTGGTCATCA
TC‐3′
Arg245Gly: 5′‐CGGGCTGAGTTTGCAGAGGGATCAGTAACCAAATTG
GAG‐3′
PCR products were cloned in Stratagene supercompetent cells XL-1.
DNAwas puriﬁed from a single colony using QIAprep SpinMiniprep Kit
(Qiagen). The presence of mutations was conﬁrmed by automatic DNA
sequencing (Laboratory of DNA Sequencing and Oligonucleotide
Synthesis, Institute of Biochemistry and Biophysics, Warsaw). Although
mutations were introduced in cDNA encoding αTM, for consistency
with the literature, numbers of substituted amino acids refer to num-
bering of amino acids in human γTM isoform (NCBI accession number
NP_689476.2), which has an additional Met residue at the N-terminus.Table 1
Myopathy-related amino acid substitutions in tropomyosin molecule.
Point
mutation
Type of
myopathy
Actin-binding
period
Position in heptapeptide
repeat
Consensus
site
Leu100Met CFTD 3 a No
Ala156Thr NM 4 a No
Arg168His CFTD/NM/CD 5 f Yes
Arg168Cys CFTD/CD 5 f Yes
Arg168Gly CFTD 5 f Yes
Lys169Glu CFTD 5 g No
Arg245Gly CFTD 7 f Yes
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Wild type tropomyosin (wtTM) and the myopathy mutants were
expressed in BL21 (DE3) cells [22] and puriﬁed as described before
[20]. Actin was isolated from chicken pectoral muscle acetone powder
according to Spudich andWatt [23].Myosin subfragment 1 (S1)was pre-
pared by papain digestion of chicken pectoral muscle myosin according
toMargossian and Lowey [24]. Heavymeromyosin (HMM)was obtained
according to [24]. Troponin was isolated from chicken pectoral muscle
with the method described by Potter, with modiﬁcations as in [25].
The concentration of actin was determined spectrophotometrically
using an extinction coefﬁcient at 290 for 0.1% actin of 0.63 and MW
42,000. Concentrations of myosin S1 and Tn were determined using
extinction coefﬁcients of 0.83 and 0.45 at 280 nm (0.1%) and MW
of proteins of 130,000 and 76,000, respectively. Concentrations of re-
combinant tropomyosins were determined by differential absorption
spectra of tyrosine (refs. in [26]).
2.3. Actin binding assay
The afﬁnity of tropomyosin for actinwasmeasured in 5 mM imidaz-
ole, pH 7.0, 150 mM NaCl, 2 mM MgCl2, 1 mM DTT, using a cos-
edimentation assay described in [27], the only exception being that
actin binding in the presence of Tn was analyzed in 300 mM NaCl.
Experimental points were collected from 2 to 4 independent experi-
ments, normalized and ﬁt to the Hill equation to obtain apparent binding
constant (Kapp).
2.4. Actin–myosin S1 ATPase activity
Measurements of the actin-S1 ATPase activity were conducted in
three types of analyses. In the ﬁrst one, the Ca-dependent regulation
of the actin–myosin ATPase activity by mutant TMs was analyzed.
Actin, myosin S1, and Tn were kept at constant 5 μM, 1 μM, and 1 μM
concentrations, whereas TM concentration was varied between 0 and
1 μM. The conditions were: 30 mM NaCl, 2 mM MgCl2, 5 mM imidaz-
ole, pH 7.0, 1 mM DTT, and either 0.1 mM CaCl2 or 0.2 mM EGTA. The
degree of activation of the actin-S1 ATPase by Ca2+ was calculated
from the activities measured in the absence of TM (A0) and the activity
observed at saturating concentrations of TM-Tn complex (Amax), using
the following equation:
Activation ¼ Amax−A0ð Þ=Amax:
The degree of inhibition obtained in the absence of Ca2+ (A0) and
saturation concentrations of TM-Tn (Amin) was expressed as:
Inhibition ¼ A0−Aminð Þ=A0:
The dependence of actin–myosin S1 ATPase activity on myosin S1
concentration was analyzed in the second type of experiment. Actin
concentration was 3 μM, TM and Tn (when present) were added at
1.5 μM and 1 μM concentration, respectively. S1 concentration was
varied between 0 and 16 μM. The ATPase activity was measured in
the buffer given above.
In the third type of experiment the Ca-sensitivity of the actin-S1
ATPase was measured. To ensure that actin was saturated by the regu-
latory proteins, 1 μM TM-Tn was added to 5 μM F-actin. S1 was subse-
quently added to 1 μM ﬁnal concentration. The experiment was
carried out under the same conditions as above, except Ca2+ concentra-
tion was increased from 1×10−9 to 1×10−5 M by varying the ratio of
Ca2+/EGTA to obtain the desired free Ca2+, as previously described
[28].
The ATPase assays were carried out in 96-well microtiter plates at
22 °C. The reaction was initiated by addingMg-ATP to the ﬁnal concen-
tration 5 mM and terminated after 6 min by adding 3.3% SDS and30 mM EDTA. The amount of inorganic phosphate released was de-
termined colorimetrically [29]. Speciﬁc activity was expressed as
μmol Pimg S1−1 min−1.
2.5. In vitro motility assay
The movement of ﬂuorescently labeled thin ﬁlaments over
HMM-covered surfaceswas observed by video ﬂuorescencemicroscopy
[30]. 2.5 μM actin ﬁlaments alone and in the presence of regulatory
proteins (0.5 μM TM, 0.5 μM Tn) were labeled with 5 μM rhodamine
phalloidin for 12–16 h before the assay, in 25 mM imidazole pH 7.0,
25 mM KCl, 4 mM MgCl2, 1 mM EGTA, 1 mM DTT (assay buffer). To
remove inactive myosin heads before the assay rabbit skeletal heavy
meromyosin (HMM) was ultracentrifuged with F-actin at 10 μM
HMM and 10 μM actin concentrations in the presence of 5 mM ATP.
HMM collected from the supernatant was bound to a coverslip coated
with Sigmacoat ﬁlm in a ﬂow cells. The ﬂow cell was washed with a
blocking buffer containing BSA (0.5 mg/ml) and then ﬂuorescently
labeled thin ﬁlaments diluted 50-fold in the assay buffer were added.
The movement of ﬂuorescently labeled thin ﬁlaments was initiated by
adding 1 mM ATP, 0.6 mg/ml glucose, 0.2 mg/ml glucose oxidase,
0.04 mg/ml catalase, 0.1 mM CaCl2 and was observed at 25 °C using
Zeiss Axio Observer Z.1 microscope equipped with a color camera
(Leica DFC 295). Filament velocity was measured on digitized video se-
quences (usually 120 frames), collected using AxioVision software
(Zeiss). Typical lapse time between the digitized frames was 1 s. The
mean velocity was calculated for all ﬁlaments in the ﬁeld of view
using the Retrac program (shareware by Nick Carter).
3. Results
3.1. Binding of tropomyosin mutant to actin
The amino acids which are directly involved in the binding of TM
to actin are arranged in groups on the outer surface of TM's coiled coil
and are known as consensus sites [17]. One can expect that mutations
affecting the consensus sites would have a larger effect on the afﬁnity
for actin than mutations in non-consensus sites. The positions of the
myopathy-causing mutations in the coiled coil are shown in Table 1
and Fig. 1. Actin afﬁnity of TM mutants in the absence and presence
of the troponin complex were examined in a direct cosedimentation
assay. Fig. 2 illustrates actin binding of wild type and mutant TMs. For
clarity the binding curves for only two of the mutants, Leu100Met-TM
and Arg168Cys-TM, are shown. The values of apparent binding con-
stants obtained for all the TMs studied are collected in Table 2. As
expected, amino acid substitutions located in the consensus sites
(Arg168 and Arg245) reduced the afﬁnity for actin alone. Surprisingly,
mutation of Ala156, which is located in the a position of the coiled
coil interface, had a similar effect as the consensus site mutations.
In contrast, substitution of Lys169 for Glu caused only a small reduc-
tion of actin afﬁnity, whereas the mutation in Leu100 was neutral
(Table 2).
Because troponin binding to the thin ﬁlament greatly enhances
TM's afﬁnity for actin, close to the sensitivity limits of our binding
assay, we increased the concentration of salt (NaCl) in the assay buffer
to 300 mM, which enabled us to compare binding of the mutant and
wild type TMs in the presence of Tn (±Ca2+). Most mutations located
in the consensus sites aswell as themutation Ala156Thr studied caused
a small decrease of TM's afﬁnity to actin in the presence of Tn and Ca2+.
Under these conditions the non-consensus site mutations, Leu100Met
and Lys169Glu, slightly increased the afﬁnity. Arg168His-TM was the
only consensus site mutant that in the presence of Tn and calcium be-
haved differently than in the absence of Tn, indicating that in terms of
actin bindingnot only the site ofmutationbut also the type of substitution
plays an important role. The removal of Ca2+ from TnC induces a shift of
the thin ﬁlament into a blocked state and a change in the orientation of
Fig. 2. The effect of myopathy causing mutations in tropomyosin on the actin afﬁnity.
Actin binding curves of wild type TM (closed triangles and solid line), Leu100Met-TM
(open circles and dashed line) and Arg168Cys-TM (open squares and dotted line) in the
absence of Tn (A), in the presence of Tn+Ca2+ (B) and in the presence of Tn-Ca2+ (C).
Conditions: 5 mM imidazole, pH 7.0, 2 mM MgCl2, 1 mM DTT and 150 mM NaCl (A) or
300 mM NaCl (B, C).
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mutants to actin, though the magnitude of the effect was different for
each of the mutants (Fig. 2C and in Table 2).Table 2
Actin afﬁnity of mutant tropomyosins in the absence and presence of Tn.
Kapp×106 (M−1)
−Tn +Tn (+Ca2+) +Tn (−Ca2+)
Wild type skTM 8.7±0.24 1.8±0.45 4.7±0.50
Leu100Met-TM 8.1±0.63 2.3±0.11 2.3±0.69
Ala156Thr-TM 3.5±0.19 0.8±0.10 2.2±0.37
Arg168His-TM 3.1±0.17 2.3±0.17 1.9±0.09
Arg168Cys-TM 2.2±0.36 1.1±0.08 2.0±0.33
Arg168Gly-TM 3.1±0.16 1.0±0.08 3.1±0.08
Lys169Glu-TM 5.6±0.37 2.7±0.21 3.3±0.41
Arg245Gly-TM 3.0±0.10 1.5±0.31 0.8±0.41
Binding of TM (0–10 μM) to 5 μM actin alone was measured in: 5 mM imidazole pH,
7.0, 1 mM DTT, 2 mMMgCl2, and 150 mM NaCl. In the presence of Tn (1.2 molar excess
over TM) 0.1 mM CaCl2 or 0.2 mM EGTA was added and the concentration of NaCl was
increased to 300 mM.3.2. Ca2+-dependent regulation of actin-activated myosin S1 ATPase
The effects of mutations on the regulatory functions of TM were
examined by following Ca-dependent changes in actin–activatedmyosin
S1 ATPase activity. First, we analyzed the activity of actin–myosin S1 as a
function of TM concentration in the presence of Tn with Ca2+ sup-
plemented (activation) or removed (inhibition) from the reaction
mixture. All studied TMs retained their normal ability to inhibit the
actin–myosin S1 ATPase activity, except for Arg168Cys-TM, which
showed signiﬁcantly reduced inhibition (Fig. 3). In contrast, all mutant
TMsweredefective in activation of theATPase, though in various degrees.
While three TMs (Leu100Met-TM, Ala156Tyr-TM, and Arg245Gly-TM)
produced activation between 50 and 90% of the activation observed in
the presence of wild type TM, mutants with substitutions in Arg168
and Lys169 did not activate the ATPase at all. Representative TMs
are illustrated in Fig. 3. Table 3 shows regulation ability of all mutants
expressed as the fraction of activation or inhibition, as described in
the Materials and methods section.
At the salt concentrations used in our actin-binding assay, myosin
S1 activity is low, which makes it difﬁcult to measure. Therefore, toFig. 3. Calcium-dependent regulation of the actin-activatedmyosin S1 ATPase. The effects
of increasing concentrations of mutant TM (inverted triangles): Leu100Met-TM
(A), Arg168His-TM (B) and Arg168Cys-TM (C), compared to wild type TM (circles)
in the presence of Tn+Ca2+ (closed symbols) and Tn-Ca2+ (open symbols) in 30 mM
NaCl, 2 mM MgCl2, 5 mM imidazole, pH 7.0, 1 mM DTT, and either 0.1 mM CaCl2 or
0.2 mM EGTA. Open diamond indicates ATPase activity of S1 alone. Other conditions as
described in the Materials and methods section.
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the solution. To ensure that under these conditions TM-Tn complex
bound to actinﬁlaments, we examined binding of wild type andmutant
tropomyosins using a co-sedimentation assay described in Materials
and methods. All studied TMs were found in pellets showing that they
were bound to actin (results not illustrated).
To check whether myopathy mutations affected the process of
switching the ﬁlament from the closed to open state, we analyzed
the effects of myopathy mutations on the actomyosin ATPase poten-
tiation by myosin S1. Fig. 4 illustrates the ATPase activity as a function
of S1 concentration. As shown in Fig. 4A, actin ﬁlament reconstructed
with wild type TM alone (no Tn), inhibited the S1 ATPase at concentra-
tions up to 10 μM S1 (1:0.3 S1: actin ratio). Higher S1 concentrations
potentiated the ATPase, which manifested itself by the ATPase activity
exceeding the level observed for unregulated actin. Ala156Tyr-TM
was the only myopathy mutant which in this function was similar to
the wild type TM (Fig. 4B). Leu100Met-TM was able to potentiate
ATPase activity, but required higher (above 14 μM) S1 concentrations
(Fig. 4C). All other mutants were inhibitory over the entire range of S1
concentrations used in this assay (Arg168Gly-TM is shown in Fig. 4D
as an example). However, as judged from the curved shapes of the
plots, the cooperativity of this process was retained and potentiation
would most probably be observed if higher S1 concentrations were
used. Unfortunately, thiswas limited by the concentrations of the isolated
proteins.
In the presence of troponin and Ca2+ the ATPase was potentiated,
but TM mutants differed in the degree of potentiation and coopera-
tivity they produced. The presence of wild type TM, Leu100Met-TM,
Ala156Thr-TMor Arg245Gly-TMwas sufﬁcient to generate potentiation
in the whole range of S1 concentrations. TMs with mutations located at
positions 168 and 169 reduced potentiation of the ﬁlament, which
means that much higher concentrations of S1 were required to switch
the ATPase from the inhibited into the activated state. Assuming
that higher S1 concentration is a measure of the inhibition TM exerts
on the ATPase activity, the mutants can be ordered as follows:
Arg168Cys-TMbArg168His-TMbLys169Glu-TMbArg168Gly-TM. In the
absence of Ca2+, Tn enhanced the inhibitory effect of mutant TMs
similarly to wild type TM. This analysis shows that myopathy-causing
mutations affect the potentiation of the actin–myosin ATPase through
impaired cooperativity withwhich the ﬁlament is switched into an active
state.
3.3. Ca-sensitivity of the actin–myosin ATPase activity
Ca-sensitivity of the thin ﬁlaments reconstructed in the presence of
mutant TMswas evaluated by analysis of theATPase activity at increasing
Ca2+ concentrations. In the presence of the TMs tested a Ca-dependentTable 3
Effect of mutations on Ca-dependent regulation and cooperative activation of the
actin–myosin S1 ATPase.
Activation (+Ca2+)a Inhibition (−Ca2+)a pCa50b
Wild type skTM 1.0 1.0 6.76±0.03
Leu100Met-TM 0.85±0.19 0.94±0.13 6.95±0.05c
Ala156Thr-TM 0.46±0.01 1.16±0.08 6.66±0.04
Arg168His-TM 0.05±0.07 0.89±0.13 7.11±0.05c
Arg168Cys-TM 0.18±0.09 0.23±0.10 6.88±0.05
Arg168Gly-TM −0.23±0.08 0.95±0.13 6.74±0.05
Lys169Glu-TM −0.17±0.14 0.95±0.18 6.86±0.04
Arg245Gly-TM 0.89±0.09 1.29±0.31 6.77±0.03
a Activation and inhibition of the actin-S1 ATPase in the presence or absence of Ca2+
were calculated as described in the Materials and methods section; the numbers show
the activity change observed in the presence of saturating concentrations of mutant
TMs in relation to the activity in the presence of wild type TM (TMm/TMwt), the negative
numbers indicate inhibition observedunder activating conditions; the datawere averaged
from 3 to 8 independent experiments; errors quoted are SEM.
b pCa values were calculated from data averaged from 2 to 6 experiments.
c pCa values signiﬁcantly different from the value obtained forwild type skTM (pb0.05).increase in activity was observed. However, in the case of the mutants
that did not potentiate the actin–myosin S1 ATPase, instead of activa-
tion a release of inhibition was measured. Normalized experimental
datawere ﬁt to theHill equation to obtain the values of Ca2+ concentra-
tion required for half maximal potentiation or release of inhibition. For
illustration purposes, two representative mutants (Arg168His-TM and
Arg245Gly-TM) were compared to skTM (Fig. 5). The mid points of
Ca-induced activity change, expressed as pCa, are collected in Table 3.
Two of the myopathy-causing mutations (Arg168His and Leu100Met)
increased sensitivity of the thin ﬁlaments to calcium concentrations.
The other mutations tested in this work did not have signiﬁcant effects.
Together the results indicate that the effects of myopathy-causing
mutations on Ca-sensitivity of the thin ﬁlaments are heterogeneous.
3.4. Effects of myopathy-causing mutations on actin ﬁlament gliding
The effects of themyopathymutations in TM on gliding of thin ﬁl-
aments reconstructed in the presence of TM and Tn complex were
analyzed in an in vitro motility assay as described in Materials and
methods. Compared to the unregulated bare ﬁlaments, binding of
TM and Tn under activating calcium concentrations resulted in an in-
crease in the fraction of motile ﬁlaments from 34±4.6 to 45±4.1% and
of their mean velocity from 5.7±0.7 to 6.7±0.3 μm/s. When mutant
TMs were bound to actin ﬁlaments, the fraction of moving ﬁlaments
and their velocities were reduced, though to various degrees (Fig. 6).
In agreement with the ATPase assay, substitutions in Arg168 and
Lys169 had the largest effects, with Arg168His being the most severe.
The removal of calcium almost completely stopped sliding of all regulated
ﬁlaments (not shown), conﬁrming thatmutations did not alter the inhib-
itory ability of the thin ﬁlament regulatory system.
4. Discussion
Mutations in the slow γ-tropomyosin gene (TPM3) can give rise to
three types of human congenital myopathies—nemaline myopathy,
cap disease and ﬁber type disproportion.
To gain insight into the molecular bases of these diseases, we
compared the functional effects of seven missense mutations using
several in vitro assays. This comparative study led us to the general
conclusion that all types of TM-dependent congenital myopathies arise
due to a reduced Ca-dependent activation of the actomyosin ATPase.
Localization of the mutations, which so far were identiﬁed in
humans, suggests that the middle region of the tropomyosin gene is
a myopathy “hot spot”. Unlike in most loci, where only one type of
substitution led to muscle pathology, three pathological mutations
were found in Arg168 [3–5,31,32]. In skeletal muscle αTM Arg167
(the counterpart of Arg168 in slow γTM) is one of the most evolutionary
conserved residues [33]. It is a part of the consensus site located in the
N-terminal half of the ﬁfth actin binding period, one of the regions,
which are most important for actin binding [34]. We provided exper-
imental evidence that in the absence of troponin all three substitu-
tions of Arg168 reduce the afﬁnity of TM for actin. The same trend was
observed in the presence of troponin without Ca2+ bound to troponin
C. Models of the skeletal muscle thin ﬁlament revealed that Arg167 is
involved in the electrostatic interactions with negatively charged
residues (Glu334 and Asp25) on actin surface [33,35,36]. Substitution
of positively charged Arg167 with uncharged Cys or Gly reduced TM's
afﬁnity for actin. The effect of Arg168His substitution suggests that
not only positive charge, but also a speciﬁc type of amino acid residue in
this position is required for binding of TM to actin with normal afﬁnity.
In agreement with the models of actin–TM complex [33,35,36], we have
demonstrated that Lys169 is not a part of the actin–TM interface. Charge
reversal in this site had a moderate effect on actin afﬁnity.
All mutations located in the central region of TM had the most
severe effects on the Ca-dependent regulation of actin–myosin interac-
tions. The thin ﬁlaments reconstructed in the presence of Arg168 and
Fig. 4. Cooperative effects of myosin S1 in the acto-S1 ATPase activity. The acto-S1 ATPase in the presence of wild type TM (A), Ala156Tyr-TM (B), Leu100Met-TM (C) and
Arg168Gly-TM alone (inverted closed triangles), with Tn+Ca2+ (closed squares), and Tn-Ca2+ (open triangles). The activity of myosin S1 alone (closed circles) and actoS1
(open circles). Conditions as given in the Fig. 3 legend and Materials and methods.
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Ca-induced activation of the actomyosin ATPase. Additionally, these
ﬁlaments had a reduced cooperativity of turning the ﬁlament into
the open, fully active state by increasing concentrations of myosin
heads. The myopathy “hot spot” is located in the actin binding period
5, which interacts with the core region of the troponin complex
[37,38] and is crucial for myosin-induced cooperative interactions
within the thin ﬁlament [36]. Details of the interactions between
all proteins binding in this region are still unresolved, thus one can
speculate that the mutations interfere with conformational changes
which turn on the ﬁlament and activate the actomyosin ATPase.
The results obtained with the Arg168 mutants might suggest that the
reduced ability of the thin ﬁlament to the Ca-dependent activation
and the myosin S1-induced potentiation of the actomyosin ATPase
correlate with the reduced afﬁnity of tropomyosin to actin. However,
the other mutants used in our study show that it is not the case—
assembly of the thin ﬁlament and regulation of actin interactions with
myosin seem unrelated. Our earlier study of the effect of a proteolytic
actin modiﬁcation on the thin ﬁlament regulation conﬁrms this notion
[39].Fig. 5. Sensitivity of the thin ﬁlaments to activating Ca2+ concentrations. The acto-S1
ATPase measured in the presence of wild type TM (closed circles and solid line),
Arg245Gly (open squares and dashed line), and Arg168His-TM (open triangles and
dashed line). Conditions as given in Fig. 3 legend and in Materials and methods.Arg245 is a consensus actin-binding residue, which is equivalent to
Arg168 [33,36]. It is located in the C-terminal region of TM, which is
shifted away from the site interacting with the troponin core region,
but it might be close to the strong binding site of TnT conservedmiddleFig. 6. The effects of myopathy mutations on the motility of thin ﬁlaments over HMM.
Velocity (A) and fraction of motile ﬁlaments (B) measured in the presence of wild type or
mutant TMs and Tn+Ca2+. Conditions as described in the Materials and methods section.
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is consistent with the localization of this residue directly in the actin–
TM interface. However, the mild reduction of Ca-induced activation
of actin–myosin ATPase activity observed in the presence of this mutant,
suggests that either Arg245 does not affect the interactions of TM with
TnT or these interactions donot play a primary role in the Ca-dependent
regulation of contraction.
Since Leu100 and Ala156 are located in the core of tropomyosin's
coiled coil, mutations in these sites should not interfere much with
actin binding. Our experiments conﬁrmed this conjecture in the
case of Leu100Met, but not in case of Ala156Thr mutant. The latter
mutation had as strong effect on actin afﬁnity as mutations of actin
binding consensus sites. It is worth noting that Ala156 is part of an
alanine cluster, where three core alanines in a row signiﬁcantly reduce
the coiled coil radius leading to a speciﬁc bend of TM [35]. Matching
shapes of actin and TMwas postulated to be a major force for assembly
of the thin ﬁlament [40], thus introduction of the more bulky and
hydrophilic threonine residue probably changed the shape and ﬂexibility
of TM's mid region and consequently led to a reduced afﬁnity for actin.
Conformational changes induced by amino acid substitutions of Leu100
and Ala156 reduced Ca-dependent activation of the actomyosin ATPase,
but the effects were less severe than in the case of mutations located in
the central region of TM. This correlates well with the location of both
residues away from the region of TM interacting with the core of the
troponin complex.
Reduced sensitivity of isometric force production to Ca2+ concentra-
tions was observed in cardiac myocytes expressing nemaline myopathy
mutant Met9Arg-TM [41]. However, analysis of the Ca-dependency of
actomyosin ATPase in solution did not show any effect of Met9Arg-TM
on this function [20]. This ﬁnding was corroborated by experiments
performed on single ﬁbers dissected from transgenic mice [42]. In con-
trast, recently published results on the contractile performance of ﬁbers
obtained from patients with TPM3-based myopathy indicated an in-
creased sensitivity of the affected ﬁbers [43]. In our work an increased
Ca-sensitivity was detected only in the presence of two (Arg168His-TM
and Leu100Met-TM) out of seven TM mutants. This suggests that
Ca-sensitivity can be altered by myopathy-causing mutations in TM,
but this defect is not common and most probably it is not the major
mechanism leading to development of the disease.
In vitro gliding velocity of heavy meromyosin-propelled thin ﬁla-
ments represents unloaded shortening of muscle ﬁbers [44]. All TM
mutants examined in this work inhibited the velocity and decreased
the number of the gliding ﬁlaments, but the most striking effect
was observed in the presence of the mutants that failed to activate
the actomyosin ATPase and showed the lowest cooperativity of the
ATPase potentiation by myosin heads. Based on the data obtained in
previous studies and this work we propose that the basic molecular
mechanism underlying muscle weakness is a defect in the activation
of actin–myosin interactions.
It is worth noting that none of the myopathy-related mutations in
TPM3were identiﬁed in TPM1, an αTM gene associated with congenital
cardiomyopathies [45]. In adult heart αTM is the predominant isoform,
thus the impaired activation of the actin–myosin cross-bridges probably
leads to a very sever contraction failure, which is lethal at early develop-
mental stages. In slow type 1 ﬁbers, γ-TM is co-expressed and forms
heterodimerswithβTM isoforms [46], which attenuates the pathological
effects.
Low level of actomyosin ATPase leads to reduced force production.
Higher proportion of slow oxidative ﬁbers in patients is regarded as a
compensatory reaction leading tomore efﬁcient energy production in the
affected muscle ﬁbers [43]. All known mutations in γTM are associated
with reduced activation of actin–myosin interactions, thus the dispro-
portion of ﬁber types, which is common to all three TPM3-dependent
myopathies, must arise from this functional defect.
Themechanism of nemaline bodies and cap formation in the affected
muscle is still an unresolved issue. Highly reduced actin afﬁnity ofMet9Arg-TM observed in earlier studies, suggested that destabilization
of the thin ﬁlaments leads to the accumulation of artiﬁcial, nonfunctional
structures containing actin [20,42]. However, this explanation seems
too simplistic. Comparison of the afﬁnities between actin and seven
myopathy-related TM mutants did not show correlation between the
afﬁnity and the formation of artiﬁcial structures. Mutants which had the
most severe effects on actin afﬁnity lead to development of myopathies
with nemaline bodies and caps, as well as to CFTD inwhich such artiﬁcial
structures do not occur.
The results of biochemical studies are invaluable in deciphering the
molecular bases of muscle diseases [45,47]. Although mixtures of
tissue-puriﬁed and recombinant proteins from different species are
commonly used in such studies, one has to bear in mind that isolated
proteins may do not reﬂect strictly the functions of their counter-
parts working in the native cell environment. However, the ﬁlaments
reconstructed from native and recombinant proteins are very useful
models suitable for comparison of the effects of different mutations
under the same conditions.
In summary, comparison of the effects of seven missense mutations
in the TPM3 gene on an array of tropomyosin functions shows that the
main defect in TM-dependent myopathies is a reduced ability of the
thin ﬁlament to activate myosin ATPase in response to Ca2+ binding
to troponin. In addition, mutations which have the strongest effects
are associated with altered cooperativity of myosin-induced activation
of the thin ﬁlament. There is no single property which distinguishes
different types of TM-dependent congenital myopathies. Therefore, the
severity of the disease must result from the accumulation of defects
caused by single mutation localized in functionally important regions
of TM.
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